MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.lungcan.2024.107934

Медицинская библиотека · Lung cancer (Amsterdam, Netherlands) · 2024

Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study.

Ferreira Marion, Swalduz Aurélie, Greillier Laurent, du Rusquec Pauline, Curcio Hubert, Raimbourg Judith, Toffart Anne-Claire, Gounant Valérie, Couraud Sebastien, De Chabot Gonzague, Friard Sylvie, Hureaux José, Jeannin Gaëlle, Odier Luc, Ricordel Charles, Wislez Marie, Descarpentries Clotilde, Herbreteau Guillaume, Missy Pascale, Morin Franck, Westeel Virginie, Cortot Alexis B

СтатьяМногоцентровое исследованиеКлиническое исследование II фазыПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Capmatinib is a selective MET inhibitor with demonstrated efficacy in a phase II study of non-small cell lung cancer (NSCLC) patients harboring METex14 mutations. However, the real-world outcomes of capmatinib are largely unknown. From June 2019, the French Early Access Program (EAP) provided capmatinib to METex14 NSCLC patients who were ineligible for or for whom first-line standard therapies had failed.

METHODS

IFCT-2104 CAPMATU was a multicenter study that included all METex14 NSCLC patients who received capmatinib as part of the EAP until August 2021. The primary endpoints were time to treatment failure (TTF), progression-free survival (PFS), overall survival (OS) and objective response rate (ORR).

RESULTS

A total of 146 patients were included. The median age was 74.9 years, 56.6 % were never-smokers, and 32.4 % had brain metastases. The median TTF, median PFS and median OS from capmatinib initiation were 5.1 months (95 % CI 4.2-6.0), 4.8 months (95 % CI 4.0-6.0) and 10.4 months (95 % CI 8.3-13.2), respectively. Evaluation of the best response to capmatinib was available for 134 patients and resulted in an ORR of 55.3 % (95 % CI 46.8 %-63.6 %). The median PFS was 7.7 months for treatment-naïve patients and 6.0 and 4.1 months for patients who had received one or 2 + prior lines of treatment, respectively. For patients with brain metastases, the median PFS was 3.0 months. Capmatinib had a known and manageable safety profile, with grade 3 to 4 adverse events, mostly peripheral edema (8.2 %), occurring in 17.8 % of patients.

CONCLUSION

In this large real-world study of METex14 NSCLC patients, the efficacy of capmatinib was confirmed, with a manageable safety profile, even in patients with brain metastases and in those who received several lines of treatment. This study reinforces the key role of capmatinib for these patients.

Для цитирования: Ferreira Marion, Swalduz Aurélie, Greillier Laurent, du Rusquec Pauline, Curcio Hubert, Raimbourg Judith, Toffart Anne-Claire, Gounant Valérie, Couraud Sebastien, De Chabot Gonzague, Friard Sylvie, Hureaux José, Jeannin Gaëlle, Odier Luc, Ricordel Charles, Wislez Marie, Descarpentries Clotilde, Herbreteau Guillaume, Missy Pascale, Morin Franck, Westeel Virginie, Cortot Alexis B. Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study.. Lung cancer (Amsterdam, Netherlands). 2024. DOI: 10.1016/j.lungcan.2024.107934.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.